ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
10.64
-0.09 (-0.84%)
Jul 20, 2026, 2:32 PM EDT - Market open
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 104 employees as of March 31, 2026. The number of employees decreased by 18 or -14.75% compared to the same quarter last year.
Employees
104
Change
-18
Growth
-14.75%
Revenue / Employee
n/a
Profits / Employee
-$1,300,135
Market Cap
1.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 104 | -18 | -14.75% |
| Dec 31, 2025 | 104 | -11 | -9.57% |
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Wave Life Sciences | 317 |
| Capricor Therapeutics | 231 |
| EyePoint | 214 |
| Cullinan Therapeutics | 109 |
| Lexicon Pharmaceuticals | 81 |
| Inventiva | 77 |
| Alto Neuroscience | 68 |
ORIC News
- 6 hours ago - ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewsWire
- 5 days ago - Oric Pharmaceuticals initiates Himalayas-1 trial - TheFly
- 5 days ago - ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - GlobeNewsWire
- 17 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Oric Pharmaceuticals resumed with a Buy at Stifel - TheFly
- 5 weeks ago - ORIC Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - ORIC Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire